Payment overview · 2025
General Payments
$293.92
15 reported records · 11 companies
Healthcare provider profile · identity verified
Michael M Packer, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · REXBURG, ID · NPI 1659454734
Verified facts
What the public records show
CMS Open Payments records show Michael M Packer, M.D. received $293.92 in general payments during 2025 across 15 reported records.
Insulet Corporation accounted for 19.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Caplyta, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Caplyta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Insulet Corporation | Unresolved — no canonical attribution shown | $57.57 | 19.6% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $47.70 | 16.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $35.27 | 12.0% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $35.17 | 12.0% | 2 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.23 | 7.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.12 | 6.8% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$18.76 | 6.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.90 | 5.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.88 | 5.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.38 | 4.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.94 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $293.92 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $57.57 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $47.70 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $35.27 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $35.27 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $35.17 | 2 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $21.23 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| INTERSTIM Normalized: interstim |
Device | Medtronic, Inc. | $18.76 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.38 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 109 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
108 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
132 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
109 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 771 | 161 |
| Atorvastatin Calcium | Atorvastatin Calcium | 729 | 165 |
| Omeprazole | Omeprazole | 609 | 139 |
| Gabapentin | Gabapentin | 520 | 102 |
| Furosemide | Furosemide | 413 | 84 |
| Amlodipine Besylate | Amlodipine Besylate | 402 | 88 |
| Eliquis | Apixaban | 356 | 46 |
| Metformin Hcl | Metformin Hcl | 332 | 81 |
| Potassium Chloride | Potassium Chloride | 326 | 58 |
| Losartan Potassium | Losartan Potassium | 315 | 85 |
| Simvastatin | Simvastatin | 313 | 80 |
| Tamsulosin Hcl | Tamsulosin Hcl | 295 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 265 | 57 |
| Sertraline Hcl | Sertraline Hcl | 264 | 56 |
| Lisinopril | Lisinopril | 256 | 62 |
| Tramadol Hcl | Tramadol Hcl | 231 | 34 |
| Metformin Hcl Er | Metformin Hcl | 227 | 60 |
| Escitalopram Oxalate | Escitalopram Oxalate | 222 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 218 | 32 |
| Trazodone Hcl | Trazodone Hcl | 216 | 42 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 210 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 209 | 54 |
| Donepezil Hcl | Donepezil Hcl | 207 | 40 |
| Meloxicam | Meloxicam | 166 | 39 |
| Glimepiride | Glimepiride | 155 | 40 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 152 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 146 | 31 |
| Valsartan | Valsartan | 139 | 30 |
| Alendronate Sodium | Alendronate Sodium | 136 | 30 |
| Carvedilol | Carvedilol | 133 | 28 |
| Jardiance | Empagliflozin | 132 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 128 | 33 |
| Allopurinol | Allopurinol | 124 | 32 |
| Alprazolam | Alprazolam | 118 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 117 | 22 |
| Ozempic | Semaglutide | 109 | 22 |
| Brilinta | Ticagrelor | 108 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 107 | 25 |
| Olanzapine | Olanzapine | 103 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 102 | 20 |
| Prednisone | Prednisone | 98 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 96 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 96 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 95 | 29 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 95 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 94 | 19 |
| Bupropion Xl | Bupropion Hcl | 92 | 20 |
| Montelukast Sodium | Montelukast Sodium | 92 | 21 |
| Xarelto | Rivaroxaban | 90 | 13 |
| Celecoxib | Celecoxib | 88 | 18 |
| Mirtazapine | Mirtazapine | 85 | 17 |
| Spironolactone | Spironolactone | 85 | 18 |
| Fentanyl | Fentanyl | 84 | 11 |
| Finasteride | Finasteride | 82 | 21 |
| Clonazepam | Clonazepam | 75 | 14 |
| Lorazepam | Lorazepam | 75 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 74 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 72 | 46 |
| Doxepin Hcl | Doxepin Hcl | 71 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 69 | 14 |
| Nystatin | Nystatin | 66 | 30 |
| Warfarin Sodium | Warfarin Sodium | 65 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 64 | 16 |
| Budesonide | Budesonide | 60 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 60 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 20 |
| Estradiol | Estradiol | 59 | 20 |
| Trintellix | Vortioxetine Hydrobromide | 59 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 56 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 55 | 19 |
| Ibuprofen | Ibuprofen | 52 | 16 |
| Lamotrigine | Lamotrigine | 52 | suppressed |
| Cefdinir | Cefdinir | 50 | 42 |
| Ezetimibe | Ezetimibe | 50 | 14 |
| Pregabalin | Pregabalin | 49 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 48 | suppressed |
| Famotidine | Famotidine | 47 | suppressed |
| Cephalexin | Cephalexin | 46 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 46 | suppressed |
| Sucralfate | Sucralfate | 46 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 45 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 12 |
| Buspirone Hcl | Buspirone Hcl | 44 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 44 | suppressed |
| Synthroid | Levothyroxine Sodium | 44 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 44 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 43 | suppressed |
| Baclofen | Baclofen | 42 | suppressed |
| Lactulose | Lactulose | 41 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 40 | 12 |
| Ketoconazole | Ketoconazole | 39 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 39 | suppressed |
| Memantine Hcl | Memantine Hcl | 38 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 37 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 36 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 35 | suppressed |
| Hydrocortisone | Hydrocortisone | 34 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 34 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 34 | suppressed |
| Torsemide | Torsemide | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 33 | 13 |
| Movantik | Naloxegol Oxalate | 33 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 32 | 11 |
| Novolog Flexpen | Insulin Aspart | 32 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 31 | suppressed |
| Fluconazole | Fluconazole | 30 | 14 |
| Gemfibrozil | Gemfibrozil | 30 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 12 |
| Caplyta | Lumateperone Tosylate | 27 | suppressed |
| Acyclovir | Acyclovir | 26 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 18 |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Azithromycin | Azithromycin | 23 | 23 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Calcitriol | Calcitriol | 23 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Austedo | Deutetrabenazine | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 20 | suppressed |
| Methimazole | Methimazole | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Renvela | Sevelamer Carbonate | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 16 |
| Daptomycin | Daptomycin | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Fluocinonide | Fluocinonide | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Haloperidol | Haloperidol | 16 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 16 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Nystop | Nystatin | 15 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Admelog Solostar | Insulin Lispro | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 14 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 14 | suppressed |
| Sulfasalazine | Sulfasalazine | 14 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Buprenorphine | Buprenorphine | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Lumigan | Bimatoprost | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 13 |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Perphenazine | Perphenazine | 13 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 13 | suppressed |
| Dalfampridine Er | Dalfampridine | 12 | suppressed |
| Dexamethasone | Dexamethasone | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Sod Sulf-Potass Sulf-Mag Sulf | Sodium, Potassium,mag Sulfates | 12 | 11 |
| Tradjenta | Linagliptin | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Trimethoprim | Trimethoprim | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $293.92 · 15 records | Insulet Corporation | AIRSUPRA, Auvelity, CAPLYTA, CAPVAXIVE, GARDASIL 9, INTERSTIM, M-M-R II, MOUNJARO, OTEZLA, Omnipod, Ozempic, Qelbree, REPATHA, ROTATEQ, VOQUEZNA, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Caplyta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error